- Last edited on February 7, 2022
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | Previous revision | ||
|
cl:psychiatric-side-effects-of-medications [on February 5, 2019] |
cl:psychiatric-side-effects-of-medications [on April 17, 2019] |
||
|---|---|---|---|
| Line 6: | Line 6: | ||
| * [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181628/|Tango, R. C. (2003). Psychiatric side effects of medications prescribed in internal medicine. Dialogues in clinical neuroscience, 5(2), 155.]] | * [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181628/|Tango, R. C. (2003). Psychiatric side effects of medications prescribed in internal medicine. Dialogues in clinical neuroscience, 5(2), 155.]] | ||
| * [[https://jamanetwork.com/journals/jama/fullarticle/2684607|Qato, D. M., Ozenberger, K., & Olfson, M. (2018). Prevalence of Prescription Medications With Depression as a Potential Adverse Effect Among Adults in the United States. JAMA, 319(22), 2289-2298.]] | * [[https://jamanetwork.com/journals/jama/fullarticle/2684607|Qato, D. M., Ozenberger, K., & Olfson, M. (2018). Prevalence of Prescription Medications With Depression as a Potential Adverse Effect Among Adults in the United States. JAMA, 319(22), 2289-2298.]] | ||
| - | |||
| - | ===== Substance/Medication-Induced Major or Mild Neurocognitive Disorder ===== | ||
| - | <WRAP group> | ||
| - | <WRAP half column> | ||
| - | == Criterion A == | ||
| - | The criteria are met for major or mild neurocognitive disorder. | ||
| - | |||
| - | == Criterion B == | ||
| - | The neurocognitive impairments do not occur exclusively during the course of a delirium and persist beyond the usual duration of intoxication and acute withdrawal. | ||
| - | |||
| - | == Criterion C == | ||
| - | The involved substance or medication and duration and extent of use are capable of producing the neurocognitive impairment. | ||
| - | |||
| - | == Criterion D == | ||
| - | The temporal course of the neurocognitive deficits is consistent with the timing of substance or medication use and abstinence (e.g., the deficits remain stable or improve after a period of abstinence). | ||
| - | |||
| - | </WRAP> | ||
| - | <WRAP half column> | ||
| - | == Criterion E == | ||
| - | The neurocognitive disorder is not attributable to another medical condition or is not better explained by another mental disorder | ||
| - | |||
| - | == Specifiers == | ||
| - | <accordion collapsed="false"> | ||
| - | <panel icon="fa fa-search-plus" size="xs" title="Substance Specifier"> | ||
| - | * Alcohol (major neurocognitive disorder), nonamnestic-confabulatory type | ||
| - | * Alcohol (major neurocognitive disorder), amnestic-confabulatory type | ||
| - | * Alcohol (mild neurocognitive disorder) | ||
| - | * Inhalant (major neurocognitive disorder) | ||
| - | * Inhalant (mild neurocognitive disorder) | ||
| - | * Sedative, hypnotic, or anxiolytic (major neurocognitive disorder) | ||
| - | * Sedative, hypnotic, or anxiolytic (mild neurocognitive disorder) | ||
| - | * Other (or unknown) substance (major neurocognitive disorder) | ||
| - | * Other (or unknown) substance (mild neurocognitive disorder) | ||
| - | </panel> | ||
| - | <panel icon="fa fa-search-plus" size="xs" title="Other Specifier"> | ||
| - | **Specify if:** | ||
| - | * Persistent: neurocognitive impairment continues to be significant after an extended period of abstinence. | ||
| - | </panel> | ||
| - | </accordion> | ||
| - | </WRAP> | ||
| - | </WRAP> | ||
| - | |||